Login to Your Account

Data from Murano helps Abbvie, waters in CLL still churning

By Randy Osborne
Staff Writer

Tuesday, December 12, 2017

ATLANTA – Abbvie Inc.'s vice president of oncology, Gary Gordon, told BioWorld that his firm aims to "restate the standard of care" in chronic lymphocytic leukemia (CLL), and the firm moved another step closer with full results from the phase III Murano trial, detailed in a late-breaking session at the American Society of Hematology meeting.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription